findmyKOL

Kathleen Moore, MD

Enriched profile

Professor, Department of Obstetrics and Gynecology; Deputy Director and Director of Phase I Clinical Trials, Fred & Pamela Buffett Cancer Center · University of Nebraska Medical Center

ORCIDNPI
Region🇺🇸 Oklahoma City, OK · South Central · United StatesSpecialtyGynecologic OncologyFocusOvarian cancer diagnosis and treatment+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2017–2026

Kathleen Moore is Professor, Department of Obstetrics and Gynecology; Deputy Director and Director of Phase I Clinical Trials, Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center. OpenAlex indexes 1,026 publications with 47,487 citations (h-index 84); ClinicalTrials.gov lists 22 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gynecologic Oncology profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Kathleen N. Moore, MD, is Professor, Department of Obstetrics and Gynecology at University of Nebraska Medical Center, Fred & Pamela Buffett Cancer Center (Omaha, NE). The public record shows 1,026 publications with 47,487 citations (h-index 84), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 41 companies, 6 NIH-funded awards (2017–2026).

  • Most recent indexed publication: 2026 · Nature reviews. Clinical oncology
  • Top research focus: Ovarian cancer diagnosis and treatment
  • 22 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 41 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic Cancer15 trialsEndometrial Neoplasms6 trialsUterine Cervical Neoplasms3 trialsCarcinoma, Adenosquamous3 trialsFallopian Tube Neoplasms3 trialsCarcinoma, Squamous Cell2 trialsSarcoma2 trialsComa2 trialsCarcinoma, Endometrioid2 trialsCarcinoma, Ovarian Epithelial2 trialsBreast Cancer1 trialCarcinoma, Small Cell1 trialPeritoneal Neoplasms1 trialAdenocarcinoma, Clear Cell1 trialCarcinosarcoma1 trialSubstance Use Disorders1 trialEndometrial Hyperplasia1 trialHyperplasia1 trialUterine Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies

Drugs & molecules

across trials, industry payments and publications
Lynparzageneric · OlaparibClinical trials1Industry payments16Publications5Opdivogeneric · NivolumabClinical trials1Industry payments1Publications3Tecentriqgeneric · AtezolizumabClinical trials1Industry payments1Publications2

Works with

trial sponsors and companies reporting payments
GlaxoSmithKline, LLC.Clinical trialsIndustry payments53Daiichi Sankyo Inc.Clinical trialsIndustry payments27Merck Sharp & Dohme LLCClinical trialsIndustry payments26

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,026publications

Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.

47,487citations

Total citations across indexed works.

84h-index

Hirsch index (OpenAlex). i10-index 336.

Clinical & industry

trials, payments and federal funding
22clinical trials

Investigator role on registered studies.

View trials
41companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
6NIH grants · 2017–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

41 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Poly(ADP-Ribose) Polymerase Inhibitor100%
    Lynparza100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

6 NIH research awards on record, funded 20172026 per NIH RePORTER. The latest:

37 more award records behind the reveal.Reveal →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/Kathleen-N-Moore-39995420

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    ocrahope.org/about/team/scientific-advisory-committee/kathleen-moore

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ocrahope.org
  • Other

    unmc.edu/newsroom/2026/03/18/kathleen-moore-md-appointed-cancer-centers-deputy-director

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • Apple Podcasts

    podcasts.apple.com/us/podcast/gynecologic-oncology-interview-with-kathleen-moore-md/id699146770

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Washington School of Medicine, Seattle, WA

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • MS in Epidemiology

    University of Oklahoma Health Sciences Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • Residency in Obstetrics and Gynecology

    Magee-Womens Hospital, University of Pittsburgh Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • Fellowship in Gynecologic Oncology

    University of Oklahoma Health Sciences Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu

Editorial & leadership roles

journal and society appointments
  • Society Treasurer

    ASCO Board of Directors, 2026–2027 term

    2027
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asco.org
  • Member

    Board of Directors, American Society of Clinical Oncology (ASCO); began a four-year term in the Designated Surgical Oncologist seat starting June 2023

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org
  • Member

    Board of Directors, GOG Foundation (Gynecologic Oncology Group Foundation)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu
5 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
4 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.